{"id":"W3033984526","doi":"10.1136/annrheumdis-2020-eular.1682","title":"FRI0087 DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Sanofi Genzyme; Gilead Sciences; LEO Pharma; Medac; Fresenius Medical Care North America; Celltrion; Astellas Pharma; Eisai; Daiichi-Sankyo; Chugai Pharmaceutical; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Pfizer; Biogen; Celgene; Bristol-Myers Squibb; Samsung; UCB Pharma; Valeant Pharmaceuticals International; Sanofi; Amgen; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Certolizumab pegol; Medicine; Discontinuation; Internal medicine; Rheumatoid arthritis; Tolerability; Psoriasis; Placebo; Surgery; Adalimumab; Immunology; Adverse effect; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003524331,0.0001584266,0.001266997,0.00007046577,0.00003061572,0.00001088624,0.000506566,0.00005457171,0.0005590141],"category_scores_gemma":[0.00604669,0.00009162137,0.000313785,0.0007489015,0.0002919838,0.0002643669,0.0003218166,0.0001422332,0.000001607069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000007851321,"about_ca_system_score_gemma":0.0001554436,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004436135,"about_ca_topic_score_gemma":0.0002681735,"domain_scores_codex":[0.9971919,0.0003721161,0.001225042,0.0003499755,0.0006679646,0.0001929817],"domain_scores_gemma":[0.9966562,0.001144531,0.000763879,0.001011229,0.0001910012,0.0002331715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0931428,0.004059084,0.8393496,0.0003667077,0.004041773,0.00000691872,0.0003017626,0.00001992544,9.071442e-7,0.00002364874,0.0005401295,0.05814673],"study_design_scores_gemma":[0.02421401,0.00154194,0.9682194,0.0004362882,0.001886287,4.508917e-7,0.0001758546,0.00322132,0.00001340642,0.00008544703,0.00009975907,0.0001058392],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952492,0.0007973893,0.000008035815,0.002263183,0.00007341071,0.0007171643,0.0008525618,0.00001087592,0.00002823456],"genre_scores_gemma":[0.9973712,0.002222522,0.0000675583,0.0002032124,0.00002244008,0.000009582828,0.00009003357,0.00001215407,0.000001322004],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1288698,"threshold_uncertainty_score":0.723889,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2336954937084066,"score_gpt":0.4422158753913258,"score_spread":0.2085203816829193,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}